Shares of Vertex Pharmaceuticals slid this morning after the company announced new trials of the hep C drug telaprevir, with full data scheduled for mid-2010. Analysts raised red flags last fall when Vertex reported mixed results from a closely watched mid-stage trial. New trials--needed because of earlier trial design flaws--will delay any final approval, allowing competing therapies from Schering-Plough and Johnson & Johnson to beat Vertex to the market. Release | Report